BridgeBio Pharma (BBIO) earnings
In the quarter ended June 2026, BridgeBio Pharma had revenue of $244M, up 120.4% on a year earlier, and diluted EPS of -0.78.
On August 10, 2026 it reported EPS of -0.78 against an estimate of -0.64 (missed).
The next report is expected on Wednesday, November 4, 2026, with EPS expected around -0.67.
Report dates
| Report | Date | Time | EPS estimate | EPS reported |
|---|---|---|---|---|
| Next | Wed Nov 4, 2026 | — | -0.67 | — |
| Last | Mon Aug 10, 2026 | — | -0.64 | -0.78 |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Quarterly results
The last 12 quarters from BridgeBio Pharma's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | $244M | +120.4% | -0.78 | — | -43.9% | 2026-08-10 |
| Mar 31, 2026 | $195M | +66.8% | -0.84 | — | -54.5% | 2026-05-07 |
| Dec 31, 2025 | $154M | +2521.2% | — | — | -90.5% | 2026-02-24 |
| Sep 30, 2025 | $121M | +4318.0% | -0.95 | — | -120.3% | 2025-10-29 |
| Jun 30, 2025 | $111M | +4999.9% | -0.95 | — | -121.4% | 2025-08-05 |
| Mar 31, 2025 | $117M | -44.8% | -0.88 | — | -89.5% | 2025-04-29 |
| Dec 31, 2024 | $6M | +237.1% | — | — | -3842.7% | 2025-02-20 |
| Sep 30, 2024 | $3M | -33.2% | -0.86 | — | -7018.7% | 2024-11-12 |
| Jun 30, 2024 | $2M | +32.1% | -0.39 | — | -8096.8% | 2024-08-01 |
| Mar 31, 2024 | $211M | +11461.9% | -0.20 | — | 0.2% | 2024-05-02 |
| Dec 31, 2023 | $2M | -6.7% | — | — | -10167.1% | 2024-02-22 |
| Sep 30, 2023 | $4M | +1110.4% | -1.08 | — | -3854.6% | 2023-11-02 |
Questions
When does BridgeBio Pharma report earnings?
BridgeBio Pharma's next earnings report is expected on November 4, 2026.
How did BridgeBio Pharma do last quarter?
In the quarter ended June 2026, BridgeBio Pharma had revenue of $244M, up 120.4% on a year earlier, and diluted EPS of -0.78.
From BridgeBio Pharma's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.